nd.capital

ND Capital (formerly NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences. Its philosophy rests on a single core belief: scientific disciplines will continue to converge, and some of the biggest breakthroughs will come from that convergence. It supports portfolio companies by operating as one integrated team across Silicon Valley, Switzerland, and the Cayman Islands, helping them bridge the Atlantic to attract capital, talent, and business partners.

The Core Investment Belief

ND Capital's stated thesis is that major breakthroughs increasingly sit at the intersection of scientific fields rather than inside a single discipline. The firm invests across the life, physical, and data sciences, and it describes its approach as spanning sectors, stages, and technologies rather than concentrating on one narrow vertical.

This belief traces back to the firm's founding. Founder and CEO Aymeric Sallin encountered nanotechnology while conducting research between the physics and chemistry departments at EPFL in the 1990s. He concluded that significant breakthroughs would arise at the nanoscale—and that distinguishing real science from science fiction would require deep expertise. That conviction became the foundation of ND Capital.

How the Firm Is Organized to Support Companies

ND Capital presents itself as operating "as one team," working together to identify and evaluate investment opportunities and to help portfolio companies succeed. In practice, this means investment decisions and company support are not split into disconnected silos.

The firm's geographic footprint is central to its support model. With teams in Silicon Valley, Switzerland, and the Cayman Islands, ND Capital positions itself to help portfolio companies "bridge the Atlantic"—connecting them to capital, talent, and business partners on both sides of the ocean. Sallin's own history reflects this: after the first ND partnership, he concluded that despite strong science in Europe, the US offered better investment opportunities, and he has commuted between Switzerland and Boston/Silicon Valley since 2007.

The Values Behind the Approach

ND Capital describes its operating stance as thinking "like company owners" and helping build "world-class, impactful, lasting companies." The firm states that it values creativity, intellect, passion, respect, and perseverance.

For founders evaluating the firm, these stated values are most useful as questions to test in conversation: Does the investor engage like an owner rather than a passive backer? Is there patience for the long timelines that deep-science companies require? The firm's emphasis on perseverance is consistent with the profile of science-heavy ventures, where technical and commercial milestones often take years.

Scale and Track Record

ND Capital reports more than $800M in assets under management (AUM) across multiple funds. Its portfolio page lists a large roster of companies labeled as alumni, indicating a substantial history of exits or graduations from its funds. The firm does not publish fund-by-fund return figures on the material reviewed here, so track record should be assessed through direct diligence—asking for references from founders of current and former portfolio companies.

What This Means If You Are Evaluating ND Capital

• Fit with the thesis: The firm is explicit that it backs convergence-driven science across life, physical, and data sciences. A company whose edge depends on combining disciplines is closer to the center of the thesis than one in a single, well-established category.
• Use of the transatlantic network: If your company needs US or European capital, hires, or partners, ask specifically how the team has delivered those connections for comparable portfolio companies.
• Owner-style engagement: Ask what board or operating involvement looks like in practice, and speak with founders who have worked with the team through difficult periods.
• Contact: The team page lists direct email addresses, including Sallin's at [email protected], alongside individual team profiles.

The clearest way to test the philosophy is to ask for concrete examples: which portfolio companies were built on cross-disciplinary science, and what the firm actually did to help them attract capital, talent, or partners across the Atlantic.

ND Capital invests across the life sciences, physical sciences, and data sciences, at multiple stages and technology types, in companies located in the United States and Europe. The firm describes itself as stage-agnostic and sector-agnostic within those broad scientific domains. Its stated focus is on "disruptive technologies" and on breakthroughs that emerge where scientific disciplines converge.

Sectors: life, physical, and data sciences

ND Capital (formerly NanoDimension) was founded in 2002 around the belief that major breakthroughs would come from the convergence of scientific fields. Its portfolio is organized into three groupings shown on the site: Physical Science, Life Science, and Data Science.

The practical implication for a founder or researcher is that the firm does not limit itself to a single vertical. A materials or energy technology, a therapeutics platform, and a data-driven tool can all fit the same thesis if the underlying science is differentiated. The firm's origin story reinforces this: its founder encountered nanotechnology while doing research between the physics and chemistry departments at EPFL and concluded that expertise would be needed "to differentiate science from science fiction."

Stages: no single-stage restriction

The site states plainly that ND Capital invests "across sectors, stages and technologies." It does not publish a stage-by-stage breakdown, fund-by-fund allocation, or check-size ranges, so you should not assume a specific entry point such as seed-only or growth-only. What the site does emphasize is how the firm works after investing: it describes itself as thinking "like company owners" and helping build "world-class, impactful, lasting companies," operating as one team to identify, evaluate, and support investments.

For a company evaluating fit, the useful signal is the science thesis and the convergence angle rather than a stage label. If your work sits at the intersection of disciplines and is defensible on scientific grounds, the stated criteria are more relevant than a funding-stage checklist.

Regions: US and Europe, with transatlantic support

ND Capital invests across the United States and Europe. It names teams in Silicon Valley, Switzerland, and the Cayman Islands, and says these teams help portfolio companies "bridge the Atlantic to attract capital, talent, and business partners."

This is the most concrete operational detail on the site, and it matters for European founders in particular. The firm's own history notes that after raising its first partnership, the founder concluded that despite strong science in Europe, the US offered better investment opportunities — and has commuted between Switzerland and Boston/Silicon Valley since 2007. A European deep-tech team should read the transatlantic bridge as a real part of the value proposition, not just marketing language.

Scale and track record signals

The named board seats give a sense of the firm's range: semiconductor/magnetic technology (Crocus), electric aviation (H55), grid-scale energy storage (Natron), and therapeutics (Tarveda, Selecta). That spread is consistent with the cross-sector, cross-stage description.

How to judge whether you fit

Use the following as a practical screen, based only on what the firm states:

• Science-first differentiation. Can you articulate why your technology is a genuine breakthrough rather than an incremental improvement?
• Convergence. Does your work draw on more than one scientific discipline? This is the firm's core stated belief.
• Geography. Are you based in, or able to operate across, the US or Europe?
• Stage openness. Do not self-screen out on stage alone, since the firm says it invests across stages — but also do not assume a specific check size, as none is published.

What the site does not disclose: fund sizes per vintage, typical investment amounts, ownership targets, or a formal pitch process. Those details would need to come from direct contact; the team page lists individual email addresses in the firstname-initials format (for example, [email protected] for the founder).

ND Capital (formerly NanoDimension) reports more than $800 million in assets under management (AUM) across multiple funds. It was founded in 2002 and invests in disruptive technologies across the life, physical, and data sciences, with teams in Silicon Valley, Switzerland, and the Cayman Islands. The firm's public site presents its portfolio and a large alumni list, but it does not publish fund-by-fund returns or exit values, so size and longevity are the verifiable facts while performance figures are not.

Scale and structure at a glance

The AUM figure is the clearest single measure of the firm's size. Because it is described as spread "across multiple funds," it reflects cumulative capital across several vehicles rather than a single pool.

What the track record evidence shows — and what it doesn't

The site supports three track-record claims:

• Operating history. Founded in 2002, the firm has been investing for more than two decades, spanning multiple fund cycles.
• Portfolio breadth. The "Portfolio" section lists current holdings across physical science and life science.
• Alumni companies. A long "Alumni" list shows companies that have moved out of the active portfolio — consistent with a firm that has held and exited positions over time.

What the site does not provide: realized returns, IRR, exit multiples, number of exits, or fund-level performance. The alumni list shows that companies have graduated from the portfolio, but it does not state whether each departure was an acquisition, IPO, shutdown, or other outcome. Treat the alumni section as evidence of activity and deal flow, not as proof of returns.

The convergence thesis behind the portfolio

ND Capital's stated core belief is that scientific disciplines will continue to converge, and that some of the biggest breakthroughs will come from that convergence. This explains why the portfolio spans life, physical, and data sciences rather than sitting in one vertical. For a reader assessing the firm, the thesis is useful context: it signals a science-heavy, cross-disciplinary approach rather than a sector-specific strategy.

Cross-border positioning

The firm describes itself as able to help portfolio companies "bridge the Atlantic" — attracting capital, talent, and business partners across the US and Europe. Founder and CEO Aymeric Sallin has commuted between Switzerland and Boston/Silicon Valley since 2007, after concluding that Europe offered strong science but the US offered better investment opportunities. For founders or co-investors, this is the practical differentiator to weigh: access to both European research ecosystems and US markets.

How to use this when evaluating ND Capital

• If you need a size benchmark: >$800M AUM and a 2002 founding date place it among established, multi-fund venture firms, not first-time managers.
• If you need performance data: request fund-level track record directly; the public site does not disclose returns or exit outcomes.
• If you are a founder: the relevant fit is stage, sector, and geography — the firm states it invests across sectors, stages, and technologies, so confirm your specific stage and region with the team rather than inferring from the site.
• If you are researching the alumni list: verify individual company outcomes independently before drawing conclusions about exit success.

The team page lists direct contact details (for example, [email protected] for the founder), which is the appropriate channel for questions the public materials do not answer.

ND Capital is a venture capital firm founded in 2002 (formerly NanoDimension) that invests in disruptive technologies across the life, physical, and data sciences. It invests across the United States and Europe, manages more than $800M in assets under management (AUM) across multiple funds, and operates through teams in Silicon Valley, Switzerland, and the Cayman Islands. It is relevant to founders, co-investors, and researchers who want to understand the firm's focus and geographic reach.

Investment focus

ND Capital's stated core belief is that scientific disciplines will continue to converge, and that some of the biggest breakthroughs will come from that convergence. Practically, that means the firm looks across sectors, stages, and technologies rather than confining itself to a single vertical.

• Life sciences — one of the three named areas of focus.
• Physical sciences — the second named area, consistent with the firm's origins in nanotechnology.
• Data sciences — the third named area, reflecting the convergence thesis.

Because the firm states it invests across stages, it does not present itself as a single-stage specialist. The site does not publish check sizes, stage-by-stage allocation, or sector-level fund breakdowns, so those specifics should be confirmed directly with the firm.

Origins and the convergence thesis

ND Capital was founded by Aymeric Sallin, who encountered nanotechnology while conducting research between the physics and chemistry departments at EPFL in the 1990s. His conclusion — that significant breakthroughs would arise at the nanoscale, and that distinguishing real science from speculation would require deep expertise — became the foundation of the firm. That history explains why a firm named for nanoscale science now describes itself as investing across converging disciplines rather than in a single technology category.

Geographic reach and cross-Atlantic support

The firm invests in both the US and Europe and describes its teams in Silicon Valley, Switzerland, and the Cayman Islands as a way to help portfolio companies "bridge the Atlantic" — attracting capital, talent, and business partners on both sides. Sallin has commuted between Switzerland and Boston/Silicon Valley since 2007, after concluding that Europe offered strong science but the US offered better investment opportunities. For a founder, the practical implication is that ND Capital positions itself as useful for transatlantic expansion, not only for capital.

How the firm says it works

ND Capital states that it operates as one team, with members collaborating to identify and evaluate opportunities and to support portfolio companies. It describes its posture as thinking like company owners and helping build "world-class, impactful, lasting companies," and it names creativity, intellect, passion, respect, and perseverance as values. These are self-descriptions rather than independently verified operating practices; they are most useful as a signal of how the firm wants to be evaluated in conversations with founders.

Track record signals

The site's portfolio section lists portfolio companies alongside a large set of "Alumni" entries, indicating a long history of exits or graduations across both the physical science and life science categories. The page does not itemize which companies are current versus alumni, so a founder or co-investor researching fit should ask for the current portfolio and recent activity directly.

Leadership

Aymeric Sallin is Founder and Chief Executive Officer and founded the firm in 2002. He previously worked as a strategy consultant at Bain & Company and serves on the boards of Crocus Technology, H55, Natron Energy, Tarveda Therapeutics, and Selecta Biosciences. He was an elected member of the World Economic Forum's Young Global Leaders Class of 2013 and of the Swiss Academy of Engineering Sciences (2016), and received the 2007 NSTI Fellow Award and a 2012 EPFL Alumni award.

When ND Capital is the right fit to approach

ND Capital is a plausible fit if your company sits at the intersection of life, physical, or data sciences, if you are building in the US or Europe (or plan to expand across the Atlantic), and if you want an investor with a science-convergence thesis rather than a single-sector mandate. It is a weaker fit if you need a published, stage-specific check size or a purely domestic single-market partner — the site does not disclose those details, so verify them before pitching.

Aymeric Sallin is the Founder & Chief Executive Officer of ND Capital, and the contact email listed on the firm's team page is [email protected]. The website's "Meet The Team" section is the place to start for leadership details and direct outreach.

Leadership at a glance

The site's team section presents Sallin's profile along with his contact address. Beyond that, the page does not list individual emails for other team members, so the published route for reaching the firm is the CEO's address above.

Aymeric Sallin's background

According to his profile on the site, Sallin founded ND Capital (formerly NanoDimension) in 2002. He became interested in nanotechnology while doing research between the Physics and Chemistry departments at EPFL in the 1990s, and that conviction—that major breakthroughs would come at the nanoscale—became the firm's foundation.

His profile also notes:

• He previously worked as a strategy consultant at Bain & Company.
• Since 2007 he has commuted between Switzerland and Boston/Silicon Valley after concluding that the US offered better investment opportunities than Europe despite strong science in Europe.
• He currently serves on the boards of Crocus Technology, H55, Natron Energy, Tarveda Therapeutics, and Selecta Biosciences.
• He was an elected member of the World Economic Forum's "Young Global Leaders" Class of 2013 and of the Swiss Academy of Engineering Sciences (2016).
• He received the "2007 NSTI Fellow Award" and a "2012 EPFL Alumni" award.

How to reach the team

1. Go to the ND Capital website (nd.capital) and open the Meet The Team section.
2. Find the profile of the person you want to contact—Aymeric Sallin's entry includes the email [email protected].
3. Write to that address with a clear subject line and a concise description of your purpose (for example, a portfolio or partnership inquiry), since the site does not publish separate contact channels for other team members.

If your question concerns the firm's investment focus or its scale, the site's "Who We Are" and "Portfolio" sections cover those topics and are worth reviewing before you write.